Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Офтальмология / Английские материалы / Oxford American Handbook of Ophthalmology_Tsai, Denniston, Murray_2011

.pdf
Скачиваний:
0
Добавлен:
28.03.2026
Размер:
11 Mб
Скачать

316 CHAPTER 11 Uveitis

Classification of uveitis (1)

The classification of uveitis may be anatomical, clinical, pathological, or etiological, and all of these may be useful in defining a uveitis entity. Anatomical classification has been formalized by the International Uveitis Study Group (ISUG) and amended by the Standardization of Uveitis Nomenclature (SUN) group (2005) (Table 11.1).

Anterior uveitis accounts for the majority of uveitis cases in Western populations. A much smaller proportion is made up of posterior, intermediate, and panuveitis.

Anatomical classification

Table 11.1 Anatomical classification of uveitis (SUN 2005)

Type

Primary site of inflammation

Includes

Anterior

Anterior chamber

Iritis

uveitis

 

Iridocyclitis

 

 

Anterior cyclitis

Intermediate

Vitreous

Pars planitis

uveitis

 

Posterior cyclitis

 

 

Hyalitis

Posterior

Retina or choroid

Focal, multifocal, or diffuse

uveitis

 

choroiditis

 

 

Chorioretinitis

 

 

Retinochoroiditis

 

 

Retinitis

 

 

Neuroretinitis

Panuveitis

Anterior chamber, vitreous

All intraocular structures

 

and retina, or choroid

 

 

 

 

Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.

Clinical classification

The most recent clinical classification of uveitis is outlined in Table 11.2. Clinical behavior may be further described in terms of onset, duration, and course of uveitis (Table 11.3).

Pathological classification

Pathological classification separates granulomatous and nongranulomatous uveitis. The term granulomatous is sometimes used in the clinical context to describe uveitis with large, greasy, mutton-fat keratic precipitates (macrophages) and iris nodules (which may include Koeppe and Busacca nodules).

CLASSIFICATION OF UVEITIS (1) 317

Table 11.2 Proposed clinical classification of uveitis (IUSG, 2005)

Group

Subgroup

Infectious

Bacterial

 

Viral

 

Fungal

 

Parasitic

 

Others

Noninfectious

Known systemic association

 

No known systemic association

Masquerade

Neoplastic

 

Non-neoplastic

 

 

Table 11.3 Descriptors of uveitis (SUN 2005)

Type

Descriptor

Definition

Onset

Sudden

 

 

Insidious

 

Duration

Limited

3 months

 

Persistent

>3 months

Course

Acute

Sudden onset + limited duration

 

Recurrent

Repeated episodes; inactive periods 3 months

 

 

off treatment

 

Chronic

Persistent; relapse in <3 months off treatment

 

 

 

Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.

However, this is strictly a histological term and is not accurate as a clinical descriptor. Indeed, this clinical picture may be seen in diseases with nongranulomatous histopathology, and true granulomatous diseases may present with nongranulomatous uveitis.

Etiological classification

An etiological classification helps define the cause, context, and treatment options for the disease, but in many patients a true etiology is never found.

318 CHAPTER 11 Uveitis

Classification of uveitis (2)

Differential diagnosis of uveitis by anatomical type

Table 11.4 Differential diagnosis of uveitis by anatomical location

Anterior

 

 

JIA

 

 

 

FHI

 

 

 

Sarcoidosis

 

 

 

Syphilis

 

 

 

Posner–Schlossman

 

 

 

Behcet’s disease

 

 

 

HSV, VZV

Intermediate

 

 

Idiopathic (pars planitis)

 

 

 

MS

 

 

 

Sarcoidosis

 

 

 

IBD

 

 

 

Lyme disease

Posterior

Retinitis

Focal

Onchocerciasis

 

 

 

Cysticercosis

 

 

 

Masquerade

 

 

Multifocal

HSV

 

 

 

VZV

 

 

 

CMV

 

 

 

Sarcoidosis

 

 

 

Masquerade

 

 

 

Candidiasis

 

Choroiditis

Focal

Idiopathic

 

 

 

Toxocariasis

 

 

 

TB

 

 

 

Masquerade

 

 

Multifocal

Sympathetic ophthalmia

 

 

 

VKH

 

 

 

Sarcoidosis

 

 

 

Serpiginous

 

 

 

Birdshot

 

 

 

Masquerade

 

 

 

MEWDS

Panuveitis

 

 

Idiopathic

 

 

 

Sarcoidosis

 

 

 

Behçet’s disease

 

 

 

VKH

 

 

 

Infective endophthalmitis

 

 

 

Syphilis

 

 

 

 

CMV, cytomegalovirus; FHI, Fuchs heterochromic iridocyclitis; HSV, herpes simplex virus; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; MEWDS, multiple evanescent white dot syndrome; MS, multiple sclerosis; POHS, presumed ocular histoplasmosis syndrome; TB, tuberculosis; VKH, Vogt–Koyanagi–Harada syndrome; VZV, varicella zoster virus.

UVEITIS: ASSESSMENT 319

Uveitis: assessment

All patients require a detailed history (ophthalmic and general) and a thorough ophthalmic examination, including dilated funduscopy of both eyes. In some cases a systemic examination may also be necessary (see Table 11.5).

For example, an apparently classic acute anterior uveitis may have posterior segment involvement (notably CME), may be secondary to more posterior disease (e.g., toxoplasmosis retinochoroiditis), or may be part of a panuveitis (e.g., sarcoid) and have systemic involvement.

Table 11.5 An approach to assessing uveitis

Symptoms

Anterior: photophobia, redness, watering, pain, dVA; may be

 

 

asymptomatic

 

 

Intermediate: floaters, photopsia, dVA

 

 

Posterior: dVA, photopsia, floaters, scotoma

 

POH

Previous episodes and investigations; surgery/trauma

 

PMH

Arthropathies (e.g., ankylosing spondylitis), chronic infections

 

 

(e.g., HSV, TB), systemic inflammation (e.g., sarcoid, Behcet’s

 

 

disease)

 

Region of systems

Detailed review of all systems

 

FH

Family members with uveitis or related diseases

 

SH

Travel or residence abroad, pets, IV drugs, sexual history

 

Drug history

Including any systemic immunosuppression

 

Allergies

Allergies or relevant drug contraindications

 

Visual acuity

Best-corrected/pinhole; near

 

 

Visual function

Check for RAPD, color vision

 

Conjunctiva

Circumcorneal injection

 

Cornea

Band keratopathy, keratic precipitates (distribution, size,

 

 

pigment)

 

AC

Flare/cells, fibrin, hypopyon

 

Gonioscopy

PAS (consider if iIOP)

 

Iris

Transillumination defects/sectoral atrophy, miosis, posterior

 

 

synechiae, heterochromia, Koeppe or Busacca nodules

 

Lens

Cataract, aphakia/pseudophakia

 

Tonometry

IOP

 

Dilated

Noncontact handheld lens ± indirect/indenting

 

funduscopy

 

 

Vitreous

Haze, cells, snowballs, opacities, subhyaloid precipitates

 

 

(KP-like but on posterior vitreous face)

 

320

CHAPTER 11 Uveitis

 

 

 

 

Table 11.5 (Contd.)

 

 

Optic disc

Disc swelling, glaucomatous changes, atrophy

 

 

Vessels

Inflammation (sheathing, leakage), ischemia (B/CRAO, B/

 

 

 

CRVO, retinal edema), occlusion

 

 

Retina

CME, unior multifocal retinitis (blurred white lesions may

 

 

 

progress to necrosis, atrophy, or pigmentation)

 

 

Choroid

Unior multifocal choroiditis (deeper yellow-white lesions),

 

 

 

associated exudative retinal detachment

 

 

 

 

 

Grading of activity

Grading of AC flare and cells is not difficult and a useful indicator of disease activity (Tables 11.6 and 11.7). Activity within the vitreous is harder to assess: quantification of vitreous cells is of limited use due to their persistence; degree of vitreous haze is a more useful indicator.

Table 11.6 Grading of AC flare

Grade

Description

0

None

1+

Faint

2+

Moderate (iris + lens clear)

3+

Marked (iris + lens hazy)

4+

Intense (fibrin or plastic aqueous)

 

 

Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.

Table 11.7 Grading of AC cells (counted with 1 x 1 mm slit)

Activity

Cells

0

<1

0.5+

1–5

1+

6–15

2+

16–25

3+

26–50

4+

>50

 

 

Reprinted with permission from Jabs DA, Nussenblatt RB, Rosenbaum JT (2005). Standardization of Uveitis Nomenclature (SUN) Working Group. Am J Ophthalmol 140:509–516.

SYMPTOMS OF SYSTEMIC DISEASE IN UVEITIS 321

Symptoms of systemic disease in uveitis

Table 11.8 Systemic review that may provide clues to underlying disease

System

Symptom

Associated disease

 

 

CVS

Chest pain—pericarditis

TB, RA, SLE

 

 

Chest pain—myocarditis

Syphilis

 

 

Palpitations

Sarcoidosis, ankylosing spondylitis,

 

 

 

syphilis, RA, SLE, HIV

 

 

Edema—cardiac failure

TB, sarcoidosis, syphilis, RA, SLE, HIV

 

 

Edema—IVC obstruction

Behçet’s disease

 

RS

Cough

TB, sarcoidosis, Wegener’s

 

 

 

granulomatosis, HIV, toxocariasis

 

 

Hemoptysis

TB, Wegener’s granulomatosis, HIV,

 

 

 

RA, SLE, sarcoidosis

 

 

Stridor

Relapsing polychondritis

 

 

Chest pain—pleuritic

Sarcoidosis, TB, Wegener’s

 

 

 

granulomatosis, SLE, RA, lymphoma,

 

 

 

HIV

 

 

Shortness of breath

Sarcoidosis, TB, Wegener’s

 

 

 

granulomatosis, SLE, RA, HIV

 

GI

Diarrhea

IBD, Behçet’s, HIV

 

 

Blood and/or mucus in stools

IBD, Behçet’s, HIV

 

 

Jaundice

IBD (with cholangitis or hepatitis)

 

 

 

 

 

toxoplasmosis, HIV

 

GU

Dysuria/discharge

Reiter’s, syphilis, TB

 

 

Hematuria

Wegener’s granulomatosis, IgA

 

 

 

nephropathy, TINU, SLE, TB

 

 

Genital ulcers

Behçet’s, syphilis, HLA-B27-related

 

 

 

disease

 

 

Testicular pain

Behçet’s, HLA-B27-related disease,

 

 

 

polyarteritis nodosum

 

ENT

Deafness or tinnitus

VKH, sympathetic ophthalmia,

 

 

 

Wegener’s granulomatosis, Cogan’s

 

 

 

syndrome

 

 

Earlobe pain and/or swelling

Relapsing polychondritis

 

 

Oral ulcers

Behçet’s, HSV, HLA-B27-related

 

 

 

disease, SLE

 

 

Sinus problems

Wegener’s granulomatosis

 

 

Recurrent epistaxis

Wegener’s granulomatosis

 

322

CHAPTER 11 Uveitis

 

 

 

Table 11.8 (Contd.)

 

 

 

 

 

 

 

 

System

Symptom

Associated disease

 

 

 

 

 

MusculoJoint pain, swelling, or

HLA-B27-related arthropathies,

 

skeletal

stiffness

JIA, sarcoidosis, RA, SLE,

 

 

 

Behçet’s, relapsing polychondritis,

 

 

 

Wegener’s, Lyme

 

 

Lower back pain

HLA-B27-related arthropathies, TB

 

Skin

Rash—erythema nodosum

Sarcoidosis, Behçet’s, TB, IBD

 

 

Rash—vesicular

HSV, VZV

 

 

Rash—other

Psoriasis, syphilis, Lyme, SLE,

 

 

 

Behçet’s, Reiter’s, JIA, TB

 

 

Photosensitivity

SLE

 

 

Vitiligo

SLE, VKH, sympathetic ophthalmia,

 

 

 

leprosy

 

 

Alopecia

SLE, VKH

 

 

Raynaud’s phenomenon

SLE, RA

 

CNS

Headaches

Sarcoidosis, VKH, Behçet’s, TB, SLE,

 

 

 

lymphoma

 

 

Seizures

Sarcoidosis, VKH, Behçet’s, SLE,

 

 

 

HIV, toxoplasmosis, lymphoma

 

 

Weakness

MS, sarcoidosis, Behçet’s, HIV,

 

 

 

leprosy, syphilis, toxoplasmosis,

 

 

 

lymphoma

 

 

Numbness and/or tingling

MS, sarcoidosis, Behçet’s, HIV,

 

 

 

leprosy, lymphoma

 

 

Loss of balance

MS, sarcoidosis, Behçet’s, VKH, HIV,

 

 

 

syphilis, lymphoma

 

 

Speech problems

MS, sarcoidosis, Behçet’s, HIV,

 

 

 

lymphoma

 

 

Behavior change

VKH, sarcoidosis, Behçet’s, SLE,

 

 

 

Wegener’s granulomatosis, HIV, TB,

 

 

 

syphilis, lymphoma

 

General

Fever/night sweats

JIA, lymphoma, VKH, SLE, RA, IBD,

 

 

 

sarcoidosis, Kawasaki disease

 

 

Swollen glands

Sarcoidosis, lymphoma, HIV, JIA, TB,

 

 

 

RA, syphilis, toxoplasmosis

 

 

 

 

 

HIV, human immunodeficiency virus; HSV, herpes simplex virus; IBD, inflammatory bowel disease; JIA, juvenile idiopathic arthritis; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; TB, tuberculosis; TINU, tubulointerstitial nephritis with uveitis; VKH, Vogt–Koyanagi–Harada syndrome; VZV, varicella zoster virus.

INVESTIGATIONS IN UVEITIS 323

Investigations in uveitis

When to investigate

Ideally, one would perform the minimum number of investigations to obtain the maximum amount of information. The usefulness of each test will depend on the pretest probability of the diagnosis and the specificity and sensitivity of the test. Consider also the potential morbidity of certain tests (e.g., FA or vitreous biopsy). In general, investigations may be performed for the following:

Diagnosis: by identifying causative or associated systemic disease; by identifying a definite etiology (e.g., an organism).

Management: monitoring disease activity or complications (e.g., OCT for macular edema); monitoring potential side effects of treatment (e.g., blood tests for some immunosuppressants).

Role in diagnosis

The etiology of most cases of uveitis is not known, although an autoimmune or autoinflammatory cause is often theorized. In most cases, a careful history and examination provides most if not all of the information need for diagnosis (see Table 11.9).

Some uveitis syndromes like FHI, Behçet’s, and toxoplasmosis are diagnosed purely on clinical grounds. Investigations are helpful in identifying uveitis of infective origin (e.g., TB, HSV) or systemic disease (e.g., lymphoma, sarcoidosis, demyelination). The role of some investigations is controversial (e.g., when to test HLA-B27 status).

Role in management

Monitoring disease

This is done almost entirely by clinical examination; however, in certain situations investigations may be helpful. For example:

Optical coherence tomography (OCT) is extremely useful in establishing macular causes of worsening vision, particularly where clinical diagnosis is difficult because of poor visualization or preexisting macular disease (e.g., epiretinal membrane, CME, macular hole); this has largely replaced FA for this purpose.

Fluorescein angiography (FA) is particularly helpful in assessing retinal vascular involvement and neovascularization.

Electroretinogram (ERG) is required for monitoring birdshot retinochoroidopathy.

Visual fields: for monitoring optic nerve damage due to either disease or associated iIOP or AZOOR complex disorders.

Monitoring therapies

Regular BP, weight, BM, and urinalysis are recommended for patients on systemic corticosteroids. Blood tests (e.g., CBC, urinalysis, LFT) are necessary for some of the other immunosuppresive agents (p. 709).

324 CHAPTER 11 Uveitis

Table 11.9 Suggested investigations in diagnosis of uveitis types

 

Investigation

Consider

Baseline

CBC

 

 

ESR

 

 

Syphilis serology

Syphilis

 

ANA (in children)

 

 

Urinalysis

TINU (protein), diabetes

 

Chest X-ray

(glucose)

 

 

TB, sarcoidosis

Selective ACE ANCA

Toxoplasma serology Toxocara ELISA Borrelia serology HLA-B27

HLA-A29

Mantoux test

FA

Electrophysiology

Ultrasound B-scan

High-resolution CT thorax

CT orbits

MRI head scan

Gallium scan

Lumbar puncture

Conjunctival biopsy

PCR of intraocular fluid

Vitreous biopsy

Choroidal biopsy

Sarcoidosis Wegener’s (PR3) Toxoplasmosis Toxocariasis Lyme disease

B27-associated disease

Birdshot retinochoroidopathy

TB, sarcoidosis

Sarcoidosis

Demyelination, sarcoidosis, lymphoma

Sarcoidosis Demyelination, lymphoma Sarcoidosis

Infection

Infection, lymphoma

Lymphoma

ACUTE ANTERIOR UVEITIS (AAU) 325

Acute anterior uveitis (AAU)

Anterior uveitis accounts for ~75–90% of all cases of uveitis. Representing a wide spectrum of disease, it may be isolated, part of a panuveitis, or part of a systemic disease.

Idiopathic acute anterior uveitis

Approximately 50% of patients with AAU have the disease in isolation (i.e., HLA-B27 negative with no underlying systemic disease). The condition affects any age (biphasic peaking at 30 and 60 years) and both sexes equally. It is almost always unilateral but may affect both eyes sequentially. Recurrences are common.

Clinical features

Pain, photophobia, redness, blurred vision.

Limbal injection, keratic precipitates (especially inferior), AC flare/cells, posterior synechiae (PS), vitreous cells.

Treatment

Treat with frequent potent topical steroid (e.g., dexamethasone 0.1% or prednisolone acetate 1% up to every 30 min initially, titrating according to disease) and dilate (e.g., cyclopentolate 1% 3x/day; atropine 1% 3x/day in severe cases)—this may be the only chance to break the synechiae. If there is poor dilation, consider subconjunctival injection of lidocaine/phenylephrine; subconjunctival dexamethasone may also be necessary.

If there is no response after 48 hours of half-hourly drops, the patient may require expert consultation (e.g., consideration of oral steroids). In recalcitrant cases, subtenons triamcinolone injections or immunosuppression may be needed to control the uveitis. More recently, biological agents such as infliximab have also been beneficial for treatment.

HLA-B27-associated AAU

Up to 50% of patients with AAU are HLA-B27 positive (cf. 8% in the general population) (see Table 11.10). HLA-B27-related disease peaks at 30 years of age, is more common in males, and is associated with a positive family history. The diagnosis may be associated with ankylosing spondylitis, Reiter’s disease, and, less commonly, psoriasis or inflammatory bowel disease (IBD).

It is almost always unilateral but may affect both eyes sequentially (alternating); rarely, it may become persistent. Inflammation is often more severe and recurrences are more frequent than in idiopathic AAU.

Clinical features

Pain, photophobia, redness, blurred vision.

Anterior segment inflammation may be severe: circumlimbal injection, keratic precipitates (especially inferior), AC flare/cells/fibrin ± hypopyon, posterior synechiae, vitreous spillover cells.

Treatment

The treatment is the same as for idiopathic AAU.